Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LITSthis companyLite Strategy, Inc.	$1.01	-0.45×	0.77×	0×	-2.13×	-83.7%	0.0%	0.0%	0.0%	-170.9%	-29.5%	-28.6%	0×	0.47×	0×	5.74×	0.0%	1	0.13	2	C
ACETAdicet Bio, Inc.	$3.11	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.64	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
HOWLWerewolf Therapeutics, Inc.	$1.05	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
NTRBNutriband Inc.	$5.70	-1.86×	8.35×	27.38×	-6.42×	-123.8%	27.8%	-408.4%	-404.1%	-123.2%	-120.1%	-9.2%	0.04×	0.54×	-369.11×	6.36×	0.0%	3	34.78	1	C-
Peer median	—	-0.86×	0.82×	0×	-0.7×	-40.7%	0.0%	0.0%	0.0%	-73.4%	-73.0%	-103.4%	0.04×	0.51×	-11.5×	6.36×	0.0%	2	-5.39	2	—